(Q53390220)

English

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

author name string

S H Park

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

M H Ryu

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

B Y Ryoo

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

S A Im

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

H C Kwon

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

S S Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

S R Park

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

B Y Kang

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

Y K Kang

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

publication date

25 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

30

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

2377-2383

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

https://scigraph.springernature.com/pub.10.1007/s10637-012-9795-9

0 references

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Imatinib mesylate--a new oral targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9795-9

21 January 2018

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants

1 reference

https://pubmed.ncbi.nlm.nih.gov/22270258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22270258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9795-9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/22270258

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53390220&oldid=1412087699"